Assessing PSMA Receptor Availability Using 68Ga-PSMA-11 PET/CT Following 177Lu-PSMA-617 Therapy Administration
There are measurable decreases in PSMA binding following 177Lu-PSMA-617 that resolve over time. As trials consider alternative therapeutic strategies, increasing dosage per cycle alone may not proportionally increase tumor uptake. Our findings warrant validation with a larger number of subjects, standardized post-therapy scan timing, and advanced pharmacokinetic analyses.
Authors
- Ka Kit Wong (ORCID: https://orcid.org/0009-0006-0837-7816)
- Molly E Roseland (ORCID: https://orcid.org/0000-0002-5885-1487)
- Yuni K. Dewaraja (ORCID: https://orcid.org/0000-0002-3920-6925)
- Zhonglin Lu
- Kellen J. Fitzpatrick (ORCID: https://orcid.org/0009-0003-6894-3443)
- Krithika Suresh
- Benjamin L. Viglianti
- Kirk A. Frey
Institutions
- University of Michigan (US)
- Michigan Medicine (US)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1097/rlu.0000000000006302
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00